Literature DB >> 26341528

Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma".

Simon J Harrison1, Hang Quach2, Andrew Spencer3, H Miles Prince4.   

Abstract

Entities:  

Keywords:  bortezomib; dexamethasone; multiple myeloma

Mesh：

Year:  2015        PMID： 26341528      PMCID： PMC4800680          DOI： 10.3324/haematol.2015.128470

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Authors:  Robert Z Orlowski; Arnon Nagler; Pieter Sonneveld; Joan Bladé; Roman Hajek; Andrew Spencer; Jesús San Miguel; Tadeusz Robak; Anna Dmoszynska; Noemi Horvath; Ivan Spicka; Heather J Sutherland; Alexander N Suvorov; Sen H Zhuang; Trilok Parekh; Liang Xiu; Zhilong Yuan; Wayne Rackoff; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2007-08-06       Impact factor: 44.544

2.  Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.

Authors:  Meletios A Dimopoulos; Robert Z Orlowski; Thierry Facon; Pieter Sonneveld; Kenneth C Anderson; Meral Beksac; Lotfi Benboubker; Huw Roddie; Anna Potamianou; Catherine Couturier; Huaibao Feng; Ozlem Ataman; Helgi van de Velde; Paul G Richardson
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

3.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

4.  The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.

Authors:  Simon J Harrison; Hang Quach; Emma Link; Huaibao Feng; Joanne Dean; Michael Copeman; Helgi Van De Velde; Anthony Schwarer; Bartrum Baker; Andrew Spencer; John Catalano; Philip Campbell; Bradley Augustson; Ken Romeril; Henry Miles Prince
Journal:  Am J Hematol       Date:  2015-02-27       Impact factor: 10.047

5.  Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.

Authors:  Meletios A Dimopoulos; Meral Beksac; Lotfi Benboubker; Huw Roddie; Nathalie Allietta; Esther Broer; Catherine Couturier; Marie-Andrée Mazier; Ralf Angermund; Thierry Facon
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.